TXMD Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
TherapeuticsMD, Inc. had $3.0M of revenue in fiscal 2025, up 71.6% on the year before. Over five years, revenue changed β45.8% a year on average.
Last close Β· Oct 23, 2026
$1.80
2.7%Hi! I read TherapeuticsMD, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+71.6%
Yes. Sales grew 71.6% last year.
Does it make a profit?
β18.8%
No. It lost money last year.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days TherapeuticsMD, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 11, 2026
Wednesday Β· in 16 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 11, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 2, 2026 | Q1 '26 | Time not announced | 8-K β |
| Mar 30, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 12, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 12, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 27, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 12, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· TherapeuticsMD, Inc. had $3.0M of revenue in fiscal 2025, up 71.6% on the year before. Over five years, revenue changed β45.8% a year on average. Its operating margin was β145.3%, up 201.8Β pts: of every 100 in sales, about β145 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· TherapeuticsMD, Inc. lost $0.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably TherapeuticsMD, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $64.9M | $49.3M | $4.3M | $5.1M | $7.5M |
| Debt incl. finance leases | $188M | β | β | β | β |
| Interest coverage | β2.4x | 6.0x | β28.4x | β611.2x | β548.8x |
| Current ratio | 0.5x | 1.2x | 1.7x | 2.4x | 3.0x |
| Quick ratio | 0.4x | 1.2x | 1.7x | 2.4x | 3.0x |
| Total assets | $169M | $90.5M | $43.3M | $38.8M | $37.7M |
| Total liabilities | $263M | $55.3M | $14.0M | $11.5M | $10.8M |
| Shareholders' equity | β$93.6M | $35.1M | $29.3M | $27.4M | $26.9M |
| Net debt (β = net cash) | $123M | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· TherapeuticsMD, Inc. passes 5 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 1 / 8 | 3 / 9 | 2 / 9 | 3 / 9 | 6 / 8 | 3 / 8 | 5 / 7 | 5 / 7 |
| Accruals ratio | β14.6% | β0.5% | β14.5% | β4.4% | β10.7% | β16.9% | 79.0% | 19.1% | β8.2% | β7.9% |
| Altman Z'' | 3.32 | 3.58 | β6.71 | β8.47 | β19.46 | β28.92 | β32.48 | β69.86 | β77.28 | β78.93 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $19.4M | $16.8M | $16.1M | $49.6M | $64.9M | $2.6M | $70.0M | $1.3M | $1.8M | $3.0M |
| Gross profit | $15.2M | $14.1M | $13.4M | $43.3M | $48.9M | $1.2M | $68.6M | $1.3M | β | β |
| Research and development | $53.9M | $33.9M | $27.3M | $19.8M | $10.4M | $7.1M | β | β | β | β |
| Operating income | β$90.3M | β$77.6M | β$130M | β$151M | β$156M | β$79.6M | $1.2M | β$8.5M | β$6.1M | β$4.4M |
| Interest expense | β | β | $4.7M | $17.4M | $28.6M | $32.9M | $0.2M | $0.3M | $0.0M | $0.0M |
| Pretax income | β$89.9M | β$76.9M | β$133M | β$176M | β$184M | β$79.3M | $1.1M | β$7.7M | β$2.3M | β$0.7M |
| Income tax | β | β | β | β | β | β | β | β$0.0M | β$0.0M | β |
| Net income | β$89.9M | β$76.9M | β$133M | β$176M | β$184M | β$172M | $112M | β$10.3M | β$2.2M | β$0.6M |
| Diluted EPS | β$0.46 | β$0.37 | β$0.59 | β$0.72 | β$0.67 | β$21.66 | $11.96 | β$0.99 | β$0.19 | β$0.05 |
| Diluted shares | 0.20B | 0.21B | 0.23B | 0.25B | 0.28B | 0.01B | 0.01B | 0.00B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$69.1M | β$76.2M | β$107M | β$166M | β$159M | β$143M | $9.4M | β$23.1M | $1.2M | $2.5M |
| Capital expenditure | $0.4M | $0.1M | $0.2M | $2.5M | $0.2M | $0.0M | β | β | β | β |
| Free cash flow | β$69.5M | β$76.2M | β$107M | β$168M | β$160M | β$143M | β | β | β | β |
| Depreciation and amortization | $0.1M | $0.2M | $0.3M | $1.4M | $4.1M | $0.7M | $1.2M | $0.9M | $0.5M | $0.4M |
| Stock-based compensation | $17.4M | $6.9M | $8.7M | $10.7M | $10.7M | $18.1M | $11.6M | $1.3M | $0.3M | $0.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $132M | $127M | $162M | $161M | $80.5M | $64.9M | $49.3M | $4.3M | $5.1M | $7.5M |
| Total debt | β | β | $73.4M | $195M | $238M | $188M | β | β | β | β |
| Current assets | $139M | $140M | $187M | $208M | $128M | $119M | $55.4M | $11.8M | $12.3M | $14.4M |
| Current liabilities | $15.0M | $13.3M | $41.1M | $53.0M | $59.2M | $253M | $46.8M | $6.9M | $5.2M | $4.8M |
| Inventory | $1.1M | $1.5M | $3.3M | $11.9M | $8.0M | $7.6M | β | β | β | β |
| Property and equipment, net | $0.5M | $0.4M | $0.5M | $2.5M | $1.9M | $0.8M | $0.1M | β | β | β |
| Intangible assets | $2.4M | $3.1M | $4.1M | $5.3M | $41.4M | $7.1M | $6.9M | $6.1M | $4.3M | $3.8M |
| Total assets | $142M | $143M | $212M | $266M | $182M | $169M | $90.5M | $43.3M | $38.8M | $37.7M |
| Total liabilities | $15.0M | $13.3M | $114M | $257M | $306M | $263M | $55.3M | $14.0M | $11.5M | $10.8M |
| Preferred stock | β | β | β | β | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | $127M | $130M | $97.5M | $9.2M | β$124M | β$93.6M | $35.1M | $29.3M | $27.4M | $26.9M |
| Margins | ||||||||||
| Gross margin | 78.4% | 84.3% | 83.0% | 87.2% | 75.4% | 45.5% | 98.0% | 100.0% | β | β |
| Operating margin | β466.3% | β462.7% | β808.8% | β304.6% | β239.8% | β3,092.8% | 1.7% | β654.6% | β347.1% | β145.3% |
| EBITDA margin | β465.6% | β461.4% | β807.0% | β301.8% | β233.5% | β3,064.2% | 3.4% | β583.8% | β318.2% | β132.6% |
| Net margin | β464.3% | β458.5% | β823.7% | β354.8% | β282.9% | β6,700.9% | 160.1% | β789.4% | β123.9% | β18.8% |
| FCF margin | β359.3% | β454.3% | β664.8% | β338.7% | β246.1% | β5,547.1% | β | β | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β1,107.1% | β277.8% | β370.0% | β211.4% | β | β | β | β |
| Return on capital employed | β70.8% | β59.8% | β76.2% | β71.0% | β127.1% | 95.4% | 2.7% | β23.4% | β18.2% | β13.4% |
| Return on equity | β70.5% | β59.8% | β116.6% | β330.1% | β | β | β | β31.9% | β7.7% | β2.1% |
| Return on assets | β63.1% | β53.9% | β74.7% | β73.7% | β82.0% | β98.2% | 86.2% | β15.4% | β5.3% | β1.5% |
| Return on tangible equity | β71.9% | β60.7% | β141.9% | β4,467.5% | β | β | 397.2% | β44.3% | β9.5% | β2.5% |
| Growth | ||||||||||
| Revenue growth | β | β13.3% | β4.0% | 208.4% | 30.7% | β96.0% | 2,619.1% | β98.1% | 35.3% | 71.6% |
| Net income growth | β | β | β | β | β | β | β | β109.2% | β | β |
| EPS growth | β | β | β | β | β | β | β | β108.3% | β | β |
| Share count change | β | 4.8% | 9.5% | 9.5% | 11.9% | β97.1% | 17.7% | β99.9% | 110,784.6% | 0.3% |
| Financial health | ||||||||||
| Debt / equity | β | β | 0.8x | 21.2x | β | β | β | β | β | β |
| Interest coverage | β | β | β27.8x | β8.7x | β5.4x | β2.4x | 6.0x | β28.4x | β611.2x | β548.8x |
| Current ratio | 9.3x | 10.5x | 4.5x | 3.9x | 2.2x | 0.5x | 1.2x | 1.7x | 2.4x | 3.0x |
| Quick ratio | 9.2x | 10.4x | 4.5x | 3.7x | 2.0x | 0.4x | 1.2x | 1.7x | 2.4x | 3.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.0% | 0.4% | 1.3% | 4.9% | 0.3% | 1.3% | β | β | β | β |
| Stock comp / revenue | 89.9% | 41.1% | 53.8% | 21.5% | 16.5% | 704.4% | 16.5% | 97.6% | 15.0% | 2.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 1.0 | 3.0 | 2.0 | 3.0 | 6.0 | 3.0 | 5.0 | 5.0 |
| Altman Z'' | 3.3 | 3.6 | β6.7 | β8.5 | β19.5 | β28.9 | β32.5 | β69.9 | β77.3 | β78.9 |
| Accruals ratio | β14.6% | β0.5% | β14.5% | β4.4% | β10.7% | β16.9% | 79.0% | 19.1% | β8.2% | β7.9% |
Source: SEC EDGAR XBRL filings (CIK 0000025743). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
